Engaging HCPs: Inhospitable

Hospitals used to be much more welcoming to pharma sales reps than they are today. Larry Dobrow looks at how the rise of the hospitalist ...

Leadership Exchange: Engaging the Digital Natives

Striking the right tone in health communications with digital-savvy Millennials is tricky. Marc Iskowitz asks seven experts for some of the keys to facilitating that ...

Therapeutic Focus 2014: Neurology

New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer's continues to frustrate patients and physicians alike. Welcome to neurology, ...

Cloud Marketing: Cloud Power

For all the talk about "the cloud," it promises most players in the pharma loop—sales and marketing execs, R&D teams and even the FDA—a better ...

Latest

Five things for pharma marketers to know: Monday, November 24

Five things for pharma marketers to know: Monday, November 24

BioMarin to acquire Dutch biotech Prosensa; Woodcock says significant efficacy key to Breakthrough Therapy designation; Stryker considers $16 billion bid for UK devicemaker Smith and Nephew.

Five things for pharma marketers to know: Friday, November 21

Five things for pharma marketers to know: Friday, November 21

EMA revises its conflict of interest policy; AbbVie all-oral HCV combo drug receives positive EU recommendation; Merck may help NewLink Genetics scale production of its Ebola vaccine.

Sanofi offers glimpse of next-gen. insulin strategy

Sanofi offers glimpse of next-gen. insulin strategy

In a company-hosted seminar today, the Paris-based drugmaker gave investors a preview of the future of its diabetes franchise.

FDA approves abuse-deterrent Hysingla ER

The first approved hydrocodone formulated to discourage misuse raises a challenge to controversial Zohydro.

World projected to spend $1T on drugs in 2018

World projected to spend $1T on drugs in 2018

The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.

Five things for pharma marketers to know: Thursday, November 20

Five things for pharma marketers to know: Thursday, November 20

CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.

Ariz. film, entertainment agency adds depth to Fingerpaint

Ariz. film, entertainment agency adds depth to Fingerpaint

With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.

Rethinking Healthcare Communications Through the Prism of Rare Diseases

Rethinking Healthcare Communications Through the Prism of Rare Diseases

Success today is predicated on recognizing that every patient is different, every disease is different, every drug, every breakthrough and every cure is different.

Unsealed court documents shed light on opioid marketing

Drug makers favor big spending on speakers' events and doctor outreach.

Gilead buys priority voucher for $125M

The scoop means the maker of HCV drugs Harvoni and Sovaldi can give any drug an accelerated review time.

Agency Spotlight


Email Newsletters

MM&M inVISION